MSMichael S. Sinha

Michael S. Sinha

*This is an algorithmically generated author record based on publicly available information.

Current Organizations / Institutes

The organizations/institutes from the scholar's latest article

Previous Organizations / Institutes

The organizations / institutes from the scholar's other articles in the past ten years


Michael S. Sinha has a total of 95 co-authors. Here are the top co-authors by number of shared publications:


Latest Publications

  • Open Access

    AI Luddites in Medicine

    by Faith K. Whatley-Blaine, Bernt Walker, Michael S. Sinha

    In the New England Journal of Medicine in 1970, physician William B. Schwartz posited that “the computer as an intellectual tool can reshape the present system of health care, fundamentally alter the role of the physician, and profoundly change the nature of … medical education.” By 1987, Schwartz had adopted a more skeptical tone: “it has become increasingly apparent that major intellectual and technical problems must be solved before we can produce truly reliable consulting programs.” Though Schwartz’s predictions were for the year 2000, the transformation he was anticipating may have begun in late 2022 with the introduction of OpenAI’s ChatGPT generative artificial intelligence (“genAI”) interface. What should physicians make of the rapidly evolving landscape of AI in health care? Some, like Dr. Robert Wachter, have leaned into genAI, recognizing its potential for advances in health care. Yet others express reservations about the integration of genAI in the health care context. This division raises an important question: what will happen to physicians who refuse to buy into the latest technology craze? Will they fall behind the times, or will they eventually be seen as rational voices in a society that quickly embraced the latest fad, for better or worse? Enter the AI Luddite. The term Luddite originated in the nineteenth-century when a group of English textile workers resisted the use of mechanized looms and knitting frames. The original Luddites believed that these new technologies diminished their bargaining power, created unsafe working conditions, and undermined established labor practices. While the Luddite movement became associated with negative connotations against the development of technology, the Luddite’s resistance to the technology advances stemmed from concerns surrounding how technological advances were implemented, who benefited from their adoption, and who bore the resulting cost. Over time, Luddite has become a derogatory label used to characterize individuals perceived as critical or skeptical of technological advances. This Essay seeks to understand the legal and ethical consequences for the clinician who resists genAI in medicine. We begin by identifying behavioral resistances to adopting genAI into the health care environment from physician, patient, and system perspectives. We also consider potential legal liability for the AI Luddite in medicine, the one who resists expectations from employers, patients, and other forces, opting instead for a “wait and see” approach. We conclude that, despite the promise of genAI in medicine, the AI Luddite may be right: some skepticism is warranted, and a full-throated embrace of the technology in its current iteration may risk running afoul of standards of care and expose physicians to liability.

  • Open Access

    Regulation as Exclusivity: Companion Diagnostics and the Persistence of Market Control in Precision Oncology

    by Corrin Smith, Michael S. Sinha

    Precision oncology increasingly relies on companion diagnostics to identify patients eligible for targeted cancer therapies. The Food and Drug Administration (FDA) frequently treats these tests as essential to the safe and effective use of corresponding drugs, embedding them in clinical trial design, regulatory approval, and product labeling. At the same time, the Supreme Court’s decisions in Mayo Collaborative Services v. Prometheus Laboratories, Inc., Association for Molecular Pathology v. Myriad Genetics, Inc., and its progeny have significantly narrowed the scope of patent protection for diagnostic methods, particularly those based on correlations between biomarkers and therapeutic outcomes. This Article argues that, despite the erosion of patent eligibility, competition in the companion diagnostics market has not meaningfully expanded. Instead, regulatory design has emerged as a functional substitute for patent protection. The integration of diagnostics into drug development, the product-specific nature of FDA approval and labeling, and the evidentiary burdens imposed by the premarket approval pathway collectively create substantial barriers to entry for follow-on diagnostics. These features operate as a form of de facto exclusivity, enabling sponsors to maintain control over diagnostic markets even in the absence of enforceable patent rights. These dynamics are further reinforced by clinical and reimbursement practices. While off-label prescribing and insurance coverage policies often expand access to oncology therapies beyond their FDA-approved indications, those practices do not similarly reduce barriers to entry for competing companion diagnostics. Physicians may prescribe therapies more flexibly than labeling contemplates, but alternative diagnostics still face substantial regulatory and evidentiary hurdles before they can be marketed or broadly adopted for use with those therapies. By situating companion diagnostics at the intersection of FDA regulation, post-Mayo patent doctrine, and oncology reimbursement practices, this Article challenges the assumption that limiting patent protection alone is sufficient to promote competition and access in companion diagnostic markets. It concludes that meaningful reform must address the structure of regulatory approval itself, including pathways for biomarker-based approval, mechanisms for demonstrating diagnostic comparability, and more flexible evidentiary standards for follow-on tests.

  • Open Access

    Patenting (USPTO) and Regulating (FDA) AI-Enabled Health Tools

    by Alexandra Kerr, Kate Sikora, Karl Gadicke, Michael S. Sinha

    This Article offers a practitioner-focused and teaching-oriented analysis of patent law challenges facing developers of health-AI tools. As artificial intelligence becomes embedded in health care delivery, health-AI developers must navigate two distinct regulatory regimes simultaneously: FDA frameworks that govern scope and classification, lifecycle change control, transparency, and explainability; and patent law doctrines that govern subject-matter eligibility, disclosure and enablement, and human-grounded inventorship. Both regimes are in transition, and practitioners who work within only one of them will routinely miss risks and opportunities created by the other.

  • Open Access

    FDA in 2050: Best-and Worst-Case Scenarios

    by Michael S. Sinha

    In 2025, the Trump administration disrupted many critical aspects of the biomedical research infrastructure in the United States. The Food and Drug Administration (FDA) was not spared. Robert F. Kennedy, Jr., a known vaccine denier with no health care experience, was confirmed as Secretary of the U.S. Department of Health and Human Services (HHS) in February 2025, followed by the confirmation of Dr. Martin Makary as Commissioner of the FDA in April. Departures of long-time FDA scientists, coupled with appointments of key personnel, seemingly because of their public stances on COVID-19 mRNA vaccines, have resulted in a tumultuous year for the agency. Though the FDA prior to the Trump administration was not without its flaws, actions by the current administration have generated unprecedented opposition. Unlike prior administrations, major policy changes have come without Congressional mandates. Opinion articles in major medical journals have largely supplanted notice and comment rulemaking. Indeed, twelve former FDA Commissioners assert that “If the goal is to rebuild confidence, the answer is not to toss aside the basic rules of science, stifle argument and oversight, or supplant expert scientific inquiry for the unilateral decision making of a few individuals.” The FDA is at a critical juncture. It could continue down this path, which might result in its ultimate destruction; or it could change course, rebuilding and fortifying the agency for generations to come. This Article speculates as to what the FDA may look like in 2050 under both best-and worst-case scenarios.

  • Open Access

    The Asexual Assumption

    by Faith K. Whatley-Blaine, Michael S. Sinha

    Inclusion-focused dating shows such as ‘Love on the Spectrum’ feature individuals with developmental or neurological disabilities on a quest for love. Despite the focus on disability representation, these shows perpetuate stigma against the disabled community by fostering an infantilizing portrayal of individuals with disabilities. This portrayal undermines the premise of encouraging meaningful romantic relationships and reinforces the stigmatizing association of asexuality with disability. This framing aligns with the broader societal narrative that individuals with disabilities are incapable of or lack interest in participating in romantic relationships or physical intimacy.The stigma that associates asexuality with disability extends beyond mere entertainment, allowing the public to justify the exclusion of individuals with disabilities from sex education and reproductive health services. This exclusion is specifically tied to the notion that individuals with disabilities cannot or should not have romantic relationships or engage in physical intimacy. In midst of an epidemic of sexual abuse against individuals with disabilities, their right to comprehensive sex education and accessible reproductive health services is vital to their well-being. Systematic exclusion from sex related services and environments contributes to a range of health and social issues, including an increased risk of sexual assault, higher risk of contracting sexually transmitted diseases, and the denial of sexual self-determination for individuals with disabilities To address this, there must a shift in media representation to focus on the capabilities of individuals with disabilities, a nationwide coalition which advocates for equitable reproductive health care, including accessibility to sex education in terms of materials and teaching methods.

  • Open Access

    Public Comment to the Office of Management and Budget: Regulation for Federal Financial Assistance

    by Michael S. Sinha

    This public comment provides a rigorous legal, clinical, and epidemiological critique of the Office of Management and Budget’s (OMB) proposed overhauls to 2 CFR Part 200, which seek to elevate the Uniform Guidance into a directly binding, highly centralized regulatory framework. The Comment argues that the proposed revisions represent an unprecedented executive overreach that violates the Administrative Procedure Act (APA), the Major Questions Doctrine, and the First and Fifth Amendments. By replacing an objective, merit-based stewardship of federal funds with ideological mandates, the proposed regulation introduces profound structural instability into the federal assistance ecosystem, threatening the foundational integrity of the nation's academic, biomedical, and health delivery infrastructure.

  • Ambient AI in Clinical Practice — The Legal Landscape of Recording Consent Requirements

    by Taylor N. Anderson, Michael S. Sinha, I. Glenn Cohen, R. Logan Jones


  • Impact of the 23andMe bankruptcy on preserving the public benefit of scientific data

    by Jonathan E. LoTempio, Christopher R. Donohue, Jonathan D. Moreno, Ana Santos Rutschman, Joshua Sarnoff, Michael S. Sinha, Thomas Stoeger, Jorge L. Contreras

    The bankruptcy of 23andMe was an inflection point for the direct-to-consumer genetics market. Although the privacy of consumer data has been highlighted by many as a concern, we discuss another key tension in this case: the corporate enclosure of scientific data that has considerable potential value for biomedical research and public health.


  • Open Access

    The Weight of Stigma

    by Rebekah A. King, Michael S. Sinha

    Many health care providers, both implicitly and explicitly, perpetuate stigma in their treatment of patients classified as obese. While medical professionals understand that a one-size-fits-all approach to treatment is ineffective, patients classified as obese are frequently offered limited treatment options that fail to account for their unique needs. Access to a range of effective treatment options has historically been limited, but new GLP-1 receptor agonist medicines like Wegovy (semaglutide) and Zepbound (tirzepatide), have shown incredible promise in addressing the obesity crisis. Unfortunately, these transformative drugs are costly, in high demand, and not widely covered by insurance, rendering them inaccessible for many Americans.This Article reviews the history of weight loss medications, emphasizing how past problems have fueled skepticism toward obesity treatment while reinforcing societal stigma against overweight individuals. Medical understanding of obesity has evolved from an issue of personal responsibility to a recognized disease, yet stigma persists. GLP-1 receptor agonist medicines have the potential to reduce structural barriers, including stigma, that deter individuals classified as obese from seeking necessary medical care. However, their effectiveness in addressing these barriers depends on expanding access. GLP-1 receptor agonists will not be universally effective, so enhanced provider education on comprehensive obesity management remains paramount. Effective medicines with strong safety profiles are an important first step, but to improve outcomes and reduce obesity stigma, physicians must adopt individualized, multi-faceted treatment plans for patients classified as obese.

  • Open Access

    Vaccines for Pandemics: Lessons from COVID-19 for H5N1 and Beyond

    by Alison McCarthy, Michael S. Sinha

    The COVID-19 pandemic brought unprecedented challenges to vaccine development and distribution. Never before has a vaccine been developed so quickly and distributed so rapidly. But compared to past pandemics and public health crises like polio or even the more recent H1N1 pandemic-the United States government's COVID-19 vaccine strategy depended greatly on the private sector. COVID-19 vaccines were credited with saving millions of lives worldwide, but private companies reaped these rewards, retained their patent rights, and profited from the vast and pressing need for their vaccines. Now, five years later, not every company views its vaccine work as a success. Financial hits in the form of stock declines (Pfizer, Moderna) or inability to reach or to remain on the domestic market for vaccines (Johnson & Johnson, AstraZeneca) may make firms more reluctant to participate in a subsequent private sector "arms race" to develop a vaccine for the next novel pathogen. Vaccine distribution followed a similar pattern. The U.S. government, through the Pharmacy Partnership for Long-Term Care Program and the Federal Pharmacy Partnership, worked with private retail pharmacies like CVS and Walgreens to distribute vaccines. West Virginia, the only state to opt out of the program, sped through its vaccine distribution while CVS and Walgreens struggled to inoculate patients.As the threat of an H5N1 pandemic looms, the United States is making many of the same mistakes that hindered its response to COVID-19. Private-public partnerships, which had mixed success during COVID-19, will still be critical to addressing H5N1 or a future disease outbreak. Yet the private sector has less incentive to enter a vaccine race than ever before, especially with vaccine skeptic Robert F. Kennedy, Jr. now at the helm of the U.S. Department of Health and Human Services (HHS). To be better prepared for future disease outbreaks, both the private and public sectors need to find a middle ground that will allow for expedient vaccine development without compromising on public interests and needs.